Skip to main content
Erschienen in: Reactions Weekly 1/2015

01.04.2015 | Case report

Gefitinib

Interstitial lung disease: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (FDA MedWatch definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * requires intervention to prevent permanent impairment or damage
Literatur
Zurück zum Zitat Zhang X, et al. Re-administration of gefitinib following diffuse interstitial lung disease in a patient with advanced lung adenocarcinoma: A case report and review of the literature. Oncology Letters 9: 2419-2421, No. 5, May 2015. Available from: URL: http://doi.org/10.3892/ol.2015.3026 - China Zhang X, et al. Re-administration of gefitinib following diffuse interstitial lung disease in a patient with advanced lung adenocarcinoma: A case report and review of the literature. Oncology Letters 9: 2419-2421, No. 5, May 2015. Available from: URL: http://​doi.​org/​10.​3892/​ol.​2015.​3026 - China
Metadaten
Titel
Gefitinib
Interstitial lung disease: case report
Publikationsdatum
01.04.2015
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2015
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-015-9943-z

Weitere Artikel der Ausgabe 1/2015

Reactions Weekly 1/2015 Zur Ausgabe

Case report

DAS-181

Case report

Indometacin

Case report

Infliximab

Case report

Topiramate

Case report

Telbivudine

Case report

Oxaliplatin